We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
3000亿美元的专利悬崖促使大型制药公司在第一季度花费840亿美元进行生物技术交易。了解哪些公司在购买以及原因。
